Navigation Links
OncoMed Pharmaceuticals and Bayer Schering Pharma Announce Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics
Date:6/17/2010

ity.  In preclinical studies of monoclonal antibody drug candidates that target Wnt signaling, OncoMed scientists have observed broad-spectrum anti-tumor and anti-cancer stem cell activity in a number of solid tumor types.

About Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of healthcare, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany.  The company combines the global activities of the Animal Health, Bayer Schering Pharma, Consumer Care and Medical Care divisions.  Bayer HealthCare's aim is to discover, manufacture and market products that will improve human and animal health worldwide.  Find more information at www.bayerhealthcare.com.

About Bayer Schering Pharma

Bayer Schering Pharma is a worldwide leading specialty pharmaceutical company.  Its research and business activities are focused on the following areas: Diagnostic Imaging, General Medicine, Specialty Medicine and Women's Healthcare.  With innovative products, Bayer Schering Pharma aims for leading positions in specialized markets worldwide.  Using new ideas, Bayer Schering Pharma aims to make a contribution to medical progress and strives to improve the quality of life. Find more information at

SOURCE OncoMed Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals Lead Antibody
2. OncoMed Pharmaceuticals Appoints Sunil Patel Senior Vice President, Corporate Development
3. OncoMed Pharmaceuticals Completes Series B Financing
4. Oramed Pharmaceuticals was Chosen to Present Two Abstracts at the 70th Scientific Sessions of the American Diabetes Association in Orlando, FL, June 25-29, 2010
5. Isis Pharmaceuticals to Discuss Its Neurodegenerative Franchise in a Conference Call on Thursday, June 17
6. Anthera Pharmaceuticals Promotes Colin Hislop, M.D., to Chief Medical Officer
7. INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc.
8. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
9. Amylin Pharmaceuticals to Present at the 2010 Jefferies Global Life Sciences Conference
10. Merrimack Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference
11. Merrimack Pharmaceuticals to Present at the Jefferies 2010 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... SAN DIEGO , June 29, 2015 ... a group of top research institutes, announced today that ... at Mount Sinai resulted in the creation of the ... two complementary single DNA molecule methods for sequencing and ... Methods , provided the comprehensive analysis of the contiguous ...
(Date:6/29/2015)... St. Louis, MO (PRWEB) , ... June 29, 2015 , ... ... July 15 – July 16 and for the fourth year in a row, will ... on what changes are taking place at the intersection of data and technology. The ...
(Date:6/26/2015)... , June 26, 2015   ... ), a pet therapeutics company focused on ... biopharmaceutical products for companion animals, today announced ... study of capromorelin (AT-002), the company,s innovative ... is a small molecule that mimics ghrelin, ...
(Date:6/26/2015)... ... June 26, 2015 , ... ... its SimplePrep™ technologies have been integrated into a sample prep module intended to ... as a part of the NASA’s WetLab-2 Project. , On June 28, 2015, ...
Breaking Biology Technology:BioNano Mapping Technology Achieves Most Contiguous Clone-free Human Genome Assembly to Date 2BioNano Mapping Technology Achieves Most Contiguous Clone-free Human Genome Assembly to Date 3StampedeCon Announces 2015 Agenda 2StampedeCon Announces 2015 Agenda 3Aratana Therapeutics Announces Positive Pivotal Results for AT-002 2Aratana Therapeutics Announces Positive Pivotal Results for AT-002 3Aratana Therapeutics Announces Positive Pivotal Results for AT-002 4Aratana Therapeutics Announces Positive Pivotal Results for AT-002 5Claremont BioSolutions’ SimplePrep™ Products Deployed in NASA Wetlab-2 Project Slated for June 28th Flight to International Space Station aboard SpaceX CRS-7 2Claremont BioSolutions’ SimplePrep™ Products Deployed in NASA Wetlab-2 Project Slated for June 28th Flight to International Space Station aboard SpaceX CRS-7 3
... ... CUNY Nobel Science Challenge. , ... New York, NY (Vocus) March 12, 2010 -- Borough of Manhattan Community College (BMCC) ... 2009 CUNY Nobel Science Challenge—as well as $5,000 as an overall Grand Prizewinner., , , ...
... Food and Drug Administration (FDA) has approved a five-day dosing regimen for Dacogen® (decitabine) for Injection to treat patients with myelodysplastic syndromes (MDS), a group of ... ... , ... ...
... ... , ... ... EDMONTON , March 11 /PRNewswire/ - Today at ACAMP,s ...
Cached Biology Technology:BMCC Student—the Only Community College Winner—Lands Grand Prize in Nobel Science Challenge 2FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 2FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 3FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 4FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 5FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 6FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 7FDA Approves Five-Day Dosing Regimen for Dacogen(R) (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS) 8Alberta companies delivering new products to the Conventional Energy marketplace 2Alberta companies delivering new products to the Conventional Energy marketplace 3
(Date:6/25/2015)...  Imagine a tool specifically designed to help you ... That,s exactly what USANA,s True Health Assessment ... health program provides a personalized approached to measuring your ... lifestyle and nutrition. At the Canadian ... USANA,s THA was honored with the Industry Innovation Award. ...
(Date:6/24/2015)... -- The biologics safety testing market is growing at ... include growth of the pharmaceutical and biological industries and ... years, the number of drug approvals in North American ... approved 225 drug applications and Health Canada approved 99. ... accounted for 3,822 of the pharmaceutical and 1,998 ...
(Date:6/24/2015)... , June 24, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced that Sharp has selected ... secure authentication for its latest flagship smartphone device, ... than 200 million shipments of its fingerprint ID ... Synaptics, strength, scalability and leadership in the biometrics ...
Breaking Biology News(10 mins):@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2
... causing urinary tract infections (UTIs), the second-most-common infection in ... with current antibiotics, according to new research from Extending ... Disease Dynamics, Economics & Policy. ETC released the ... to track changes in antibiotic drug use and resistance. ...
... Nov. 13, 2012 Millions of laboratory tests and ... processes. Quantum Materials Corporation has now developed tetrapod ... gain knowledge of how body systems function and chronic ... health and longevity. Conventionally, fluorescent tags or ...
... $15,000 in a national competition for adapting a traditional ... villagers can use to make paper for their children,s ... of a machine to convert farm waste to paper, ... Houston during a ceremony honoring top submissions in the ...
Cached Biology News:Second most common infection in the US proving harder to treat with current antibiotics 2Second most common infection in the US proving harder to treat with current antibiotics 3Second most common infection in the US proving harder to treat with current antibiotics 4High Brightness Tetrapod Quantum Dots Developed 2High Brightness Tetrapod Quantum Dots Developed 3Plan to turn farm waste into paper earns students $15,000 2
... smallest electronic pressure controller available measuring 26 ... this unit specifically for the analytical instrumentation ... carrier gas flow control, microfluidic flow control, ... focusing, the OEM-EPC offers external pressure sensor ...
... Flow) offers the same benefits as the VSO ... control is critical or flow is required below ... flow of gas in proportion to the input ... pulse width modulation; closed loop feedback delivers optimal ...
...
... Serum is obtained from non-demolished ... healthy, fasted donors. The donors ... way and are maintained on ... Total Protein Concentration : 85 ...
Biology Products: